1. Home
  2. CNS vs AMLX Comparison

CNS vs AMLX Comparison

Compare CNS & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

SELL

Current Price

$69.86

Market Cap

3.6B

Sector

Finance

ML Signal

SELL

Logo Amylyx Pharmaceuticals Inc.

AMLX

Amylyx Pharmaceuticals Inc.

SELL

Current Price

$27.76

Market Cap

3.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CNS
AMLX
Founded
1986
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.8B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
CNS
AMLX
Price
$69.86
$27.76
Analyst Decision
Hold
Strong Buy
Analyst Count
3
11
Target Price
★ $69.33
$43.00
AVG Volume (30 Days)
202.8K
★ 1.3M
Earning Date
10-15-2026
11-05-2026
Dividend Yield
★ 3.76%
N/A
EPS Growth
N/A
★ 65.46
EPS
★ 2.58
N/A
Revenue
★ $427,536,000.00
$380,786,000.00
Revenue This Year
$9.41
N/A
Revenue Next Year
$5.94
$56,076.69
P/E Ratio
$27.66
★ N/A
Revenue Growth
4.07
★ 1612.94
52 Week Low
$58.39
$10.83
52 Week High
$86.56
$41.14

Technical Indicators

Market Signals
Indicator
CNS
AMLX
Relative Strength Index (RSI) 42.05 45.03
Support Level $69.20 $26.49
Resistance Level $73.34 $29.30
Average True Range (ATR) 2.38 1.81
MACD -0.18 0.11
Stochastic Oscillator 6.30 9.33

Price Performance

Historical Comparison
CNS
AMLX

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.

About AMLX Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Share on Social Networks: